Insight

Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC

Photo from clinicaloptions.com

Sep 12, 2024, 09:48

Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC

Erman Akkus shared a post on X about a recent paper by Myung-Ju Ahn et al. published in JCO.

“Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study”

Authors: Myung-Ju Ahn, Kentaro Tanaka, Luis Paz-Ares, Aaron Lisberg, Jacob Sands et al.

“Datopotamab deruxtecan vs docetaxel for previously treated advanced NSCLC.

TROPION-Lung01

Improved PFS in nonsquamous histology
5.5 vs3.6 mo, HR: 0.63 (0.51-0.79)
Not OS
Not PFS or OS in squamous histology.”

Source: Erman Akkus/X

Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.

Aaron Lisberg cancer Dato-DXd datopotamab deruxtecan docetaxel Erman Akkus Jacob Sands JCO Kentaro Tanaka Luis Paz-Ares metastatic non-small cell lung cancer mNSCLC Myung-Ju Ahn NSCLC OncoDaily Oncology TROPION-Lung01

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage